Quantcast
Channel: Debjit Chattopadhyay – BioTuesdays
Browsing latest articles
Browse All 17 View Live

Image may be NSFW.
Clik here to view.

HCW starts Precision BioSciences at buy; PT $21

H.C. Wainwright initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $13.76 on July 15. Precision is one of the early adopters of a...

View Article



Image may be NSFW.
Clik here to view.

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the...

View Article

Image may be NSFW.
Clik here to view.

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its...

View Article

Image may be NSFW.
Clik here to view.

HCW starts Stoke Therapeutics at buy; PT $30

H.C. Wainwright launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and price target of $30. The stock closed at $22.86. Analyst Debjit Chattopadhyay writes that Stoke is...

View Article

Image may be NSFW.
Clik here to view.

HCW ups Mersana Therapeutics PT to $12 from $7

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s...

View Article


Image may be NSFW.
Clik here to view.

HCW starts Molecular Partners at buy; PT CHF29

H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing...

View Article

Image may be NSFW.
Clik here to view.

HCW starts Bicycle Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which...

View Article
Browsing latest articles
Browse All 17 View Live




Latest Images